Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Counterdetailing Influenza Treatments Relenza and Tamiflu

Executive Summary

FDA is taking action to curb inappropriate prescribing of Glaxo Wellcome's Relenza and Roche's Tamiflu.

You may also be interested in...



Roche Tamiflu Celebrity Endorsement Ad Challenged By FDA

Celebrity endorsements of prescription drugs must be carefully qualified to avoid overstating efficacy, FDA told Roche in a letter objecting to a radio broadcast commercial for the flu therapy Tamiflu (oseltamivir)

FDA User Fees Could Fund Responses To DTC Ads, AARP Says

The federal government should sponsor public information campaigns to supplement the information supplied by direct-to-consumer advertising of pharmaceuticals, an AARP Public Policy Institute "issue paper" on DTC ads states.

FDA User Fees Could Fund Responses To DTC Ads, AARP Says

The federal government should sponsor public information campaigns to supplement the information supplied by direct-to-consumer advertising of pharmaceuticals, an AARP Public Policy Institute "issue paper" on DTC ads states.

Related Content

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel